Overview

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To assess the feasibility of using intra-tumoral PF-3512676 in combination with local radiation as a therapy for lowgrade b-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Ronald Levy
Collaborator:
Pfizer